Unexplored pharmacokinetic opportunities with microdosing in oncology

Clinical Cancer Research

Volumn 13, Issue 14, 2007, Pages 4033-4034

  Sparreboom, Alex ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A4; IMATINIB;

AEROBIC METABOLISM; CHRONIC MYELOID LEUKEMIA; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG METABOLISM; EDITORIAL; ENVIRONMENTAL FACTOR; FOOD AND DRUG ADMINISTRATION; GENETIC VARIABILITY; GENOTYPE; HEREDITY; HUMAN; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MICRODOSIMETRY; PHARMACOGENETICS; PHENOTYPE; PRESCRIPTION; PRIORITY JOURNAL; SINGLE DRUG DOSE;

ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; NEOPLASMS; PIPERAZINES; PYRIMIDINES;

EID: 34547100044     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-0540     Document Type: Editorial

References (16)

1. Twombly R. Slow start to phase 0 as researchers debate value. J Natl Cancer Inst 2006;98:804-6.
2. Kummar S, Kinders R, Rubinstein L, et al. Compressing drug development timelines in oncology using phase '0' trials. Nat Rev Cancer 2007;7:131-9.
3. Garner RC, Lappin G. The phase 0 microdosing concept. Br J Clin Pharmacol 2006;61:367-70.
4. 14C-labeled (R)-6-[amino(4-chlorophenyl)(1-methyl-1H- imidazol-5-yl)methyl]-4-(3-chlorophenyl)1-methyl-2(1H)-quinolinone (R115777), a farnesyl transferase inhibitor. Drug Metab Dispos 2002;30:823-30.
5. Eap CB, Buclin T, Cucchia G, et al. Oral administration of a low dose of midazolam (75 microg) as an in vivo probe for CYP3A activity. Eur J Clin Pharmacol 2004;60:237-46.
6. Boddy AV, Sludden J, Griffin M, et al. Pharmacokinetic investigation of imatinib in patients with chronic myeloid leukemia using accelerator mass spectrometry. Clin Cancer Res 2007;13:4164-9.
7. Picard S, Titier K, Etienne G, et al.T rough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 2007;109:3496-9.
8. Lappin G, Kuhnz W, Jochemsen R, et al. Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs. Clin Pharmacol Ther 2006;80:203-15.
9. Dutreix C, Peng B, Mehring G, et al. Pharmacokinetic interaction between ketoconazole and imatinib mesylate (Glivec) in healthy subjects. Cancer Chemother Pharmacol 2004;54:290-4.
10. Peng B, Lloyd P, Schran H. Clinical pharmacokinetics of imatinib. Clin Pharmacokin 2005;44:879-94.
11. Lappin G, Rowland M, Garner RC. The use of isotopes in the determination of absolute bioavailability of drugs in humans. Expert Opin Drug MetabToxicol 2006;2:419-27.
12. Gardner ER, Burger H, van Schaik RH, et al. Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib. Clin Pharmacol Ther 2006;80:192-201.
13. Deeken J, Figg WD, Bates SE, et al. Toward individualize treatment: prediction of anticancer drug disposition and toxicity with pharmacogenetics. Anticancer Drugs 2007;18:111-26.
14. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates ? Nat Rev Drug Discov 2004;3:711-5.
15. Boyd RA, Lalonde RL. Nontraditional approaches to first-in-human studies to increase efficiency of drug development: will microdose studies make a significant impact? Clin Pharmacol Ther 2007;81:24-6.
16. Kil KE, Ding YS, Lin KS, et al. Synthesis and positron emission tomography studies of carbon-11-labeled imatinib (Gleevec). Nucl Med Biol 2007;34:153-63.